Company Description
Origin Life Sciences is a clinical-stage biotechnology company that has been developing a proprietary patented high-energy plasma device that generates nitric oxide (“NO”) in the form of a plasma/NO stream and delivers it to targeted locations of the body.
The stream can potentially be used for various therapeutic purposes, including as an anti-infective, anti-inflammatory and tissue-regenerative therapy for chronic wounds and skin and soft tissue infections.
The U.S. Food and Drug Administration previously determined that our product will be a Class III medical device.
The cornerstone of the plasma/NO therapy is our patented delivery platform named “Ionojet” which allows us to turn atmospheric air into a plasma/NO stream that has been shown in investigations: (i) to be non-toxic, (ii) to generate NO activity up to 3 cm below the skin, and (iii) to stimulate sustained biological activity in tissue for up to an hour after delivery of the therapy.
To date, our clinical activities have been focused on our dose-ranging feasibility clinical trial for the treatment of diabetic foot ulcers completed in 2018 using the plasma/NO stream generated from our Ionojet, and the preparation for our planned pivotal clinical trial, including finalization of the prototype of the Ionojet that we intend to use in our pivotal trial.
| Country | United States |
| Founded | 2010 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 7 |
| CEO | Michael Preston |
Contact Details
Address: 2 Research Way, Third Floor Princeton, NJ 08540 United States | |
| Phone | (609) 250-6000 |
| Website | originww.com |
Stock Details
| Ticker Symbol | OLSI |
| Exchange | NYSEAMERICAN |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $4.00 |
| CIK Code | 0001573901 |
| Employer ID | 27-3705184 |
| SIC Code | 3845 |
Key Executives
| Name | Position |
|---|---|
| Michael Preston | Chairman and Chief Executive Officer |
| David Dantzker, M.D. | Deputy Chairman and Chief Medical Officer |
| John Fernandes | Chief Financial Officer |
| Terry Treadwell, M.D. | Chief Clinical Officer (effective upon completion of this offering) |
| Anthony Brampton | Non-Executive Director |
| Victor Micati | Non-Executive Director |
| Howard Nelson | Non-Executive Director |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Feb 2, 2024 | S-1/A | [Amend] General form for registration of securities under the Securities Act of 1933 |
| Jan 10, 2024 | S-1/A | [Amend] General form for registration of securities under the Securities Act of 1933 |
| Dec 19, 2023 | S-1/A | [Amend] General form for registration of securities under the Securities Act of 1933 |
| Oct 17, 2023 | D | Notice of Exempt Offering of Securities |
| Sep 29, 2023 | S-1/A | [Amend] General form for registration of securities under the Securities Act of 1933 |
| Jun 29, 2023 | S-1/A | [Amend] General form for registration of securities under the Securities Act of 1933 |
| Jun 22, 2023 | D/A | Filing |
| Jun 21, 2023 | S-1/A | [Amend] General form for registration of securities under the Securities Act of 1933 |
| Jun 5, 2023 | S-1/A | [Amend] General form for registration of securities under the Securities Act of 1933 |
| Jun 1, 2023 | D | Notice of Exempt Offering of Securities |